Allergy

New findings from the 12-week pivotal JADE MONO-1 trial show the JAK1 inhibitor's benefit in skin clearance and itch relief.

How drug classes such as biologics have given dermatologists confidence in clearing patients' skin.

The United States Food and Drug Administration has accepted a BLA for Viaskin Peanut from DBV Technologies for the treatment of peanut-allergic children ages 4 to 11, which previously withdrew a BLA in 2018 after request from the FDA requested additional data on its manufacturing procedures and quality controls.

New phase 2b data shows the JAK1 inhibitor is beneficial for moderate to severe adult atopic dermatitis.

How new agents, improved study outcomes, and priority on diagnosis has bettered the state of dermatologic care.

After receiving FDA approval for add-on adult severe chronic rhinosinusitis with nasal polyps treatment this June, the biologic has reported significant improvement in 24- and 52-week outcomes.

The Allergenic Products Advisory Committee voted in favor Friday to support the BLA data for what could become the first drug indicated for food allergy desensitization.

A new extended trial for the liquid immunotherapy shows two-thirds of allergic children were able to consume at least 750 mg of peanut after 3-5 years.

The JAK inhibitor previously approved for rheumatoid arthritis has reported early primary endpoint outcomes in its ongoing phase 3 trial.

A 600-city analysis of particulate matter found daily exposure is linked to worsened mortality rates, particularly in areas with higher mean temperatures.

The epicutaneous immunotherapy patch BLA was previously submitted to the FDA last year, but withdrawn due to concerns over manufacturing procedure and quality control.

New phase 3 data will evidence an FDA application for the biologic as an add-on therapy for patients aged 6-11 years with AD.

A new cohort shows FLG loss-of-function variations are often different among AD pediatric patients with different ancestries.

The burdensome, inflammatory chronic condition is highlighted by difficult diagnoses and screening options. How is research advancing to improve care?

After showing the ability to regain patients' senses of smell and taste in a pair of phase 3 trials, the biologic becomes the first indicated for CRSwNP.

This ad was supported by Church & Dwight Co. Inc, featuring Feryal Hajee, MD.

The real-world analysis of epicutaneous therapy for milk-related EoE progressively exposed pediatric patients to their milk allergen.

Early research found that e-cigarette use affects the immune system response to the flu virus and the effects are different for female and male users.

The Submitted Biologics Application for AR101, the first potential pediatric food allergy preventive therapy, will be considered on September 13.

Patients on 2 different doses of the once-daily oral JAK1 inhibitor reached statistically significant measures for improved symptoms.

Filters that break up the exhaust from diesel engines are intended to decrease the health impacts of heavy roadway traffic, but a new study suggests the opposite might be happening in some cases.

Both parents and children with atopic dermatitis often lack answers when it comes to the possibility that food allergies might be causing their skin irritations.

In a study that builds upon the hypothesis, researchers say early-in-life health factors can have an impact on adults’ health.

A new NIH-funded study showed that patients with atopic dermatitis may increase their risk of food allergies when they scratch their skin.

A new study from Canada found children as young as 9 months of age can safely undergo the desensitization treatment routinely.

Investigators found that peanut allergy immunotherapy was associated with a greater risk of anaphylaxis, epinephrine use, and serious adverse events compared to avoidance or placebo.

Patients who suffer from pollen allergies are likely to face more severe symptoms and longer allergy seasons as a result of global warming.

Sublingual allergy tablets are becoming a common treatment option among allergists, though they remain a back-up choice in the eyes of many physicians.

The investigative solution improved patient metrics for itching, and could be considered for FDA submission later this year.

Aimmune announced AR101 phase 3 trial reached its primary efficacy endpoint, intent to submit marketing authorization application.